bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1 from Salivary microRNAs Show Potential as a Noninvasive Biomarker for Detecting Resectable Pancreatic Cancer
Authors: Xie Zijun , Yin Xiaoyu , Gong Bo , Nie Wenjing , Wu Bin , Zhang Xuchao , Huang Jian , Zhang Pingyou , Zhou Zhiwei , Li Zijun
Published: April 2023

Supplementary Figure 1. Brief schematic of the strategy to identify salivary miRNA biomarkers to detect resectable pancreatic cancer.
Supplementary Figure 1 from Inhibition of Tumor Promotion by Parthenolide: Epigenetic Modulation of p21
Authors: Ghantous Akram , Saikali Melody , Rau Tilman , Gali-Muhtasib Hala , Schneider-Stock Regine , Darwiche Nadine
Published: April 2023

PDF file - 127K, Parthenolide inhibits TPA-induced tumor promotion and NF-kappaB luciferase activity
Perspective on This Article from Randomized Phase II Trial of Lyophilized Strawberries in Patients with Dysplastic Precancerous Lesions of the Esophagus
Authors: Chen Tong , Yan Fei , Qian Jiaming , Guo Mingzhou , Zhang Hongbing , Tang Xiaofei , Chen Fang , Stoner Gary D. , Wang Xiaomin
Published: April 2023

Perspective on This Article from Randomized Phase II Trial of Lyophilized Strawberries in Patients with Dysplastic Precancerous Lesions of the Esophagus
Commentary on This Article from A Randomized, Placebo-Controlled, Preoperative Trial of Allopurinol in Subjects with Colorectal Adenoma
Authors: Puntoni Matteo , Branchi Daniela , Argusti Alessandra , Zanardi Silvia , Crosta Cristiano , Meroni Emanuele , Munizzi Francesco , Michetti Paolo , Coccia Gianni , De Roberto Giuseppe , Bandelloni Roberto , Turbino Laura , Minetti Egle , Mori Marco , Salvi Sandra , Boccardo Simona , Gatteschi Beatrice , Benelli Roberto , Sonzogni Angelica , DeCensi Andrea
Published: April 2023

Commentary on This Article from A Randomized, Placebo-Controlled, Preoperative Trial of Allopurinol in Subjects with Colorectal Adenoma
Supplementary Figure 1 from A Multiplexable, Microfluidic Platform for the Rapid Quantitation of a Biomarker Panel for Early Ovarian Cancer Detection at the Point-of-Care
Authors: Shadfan Basil H. , Simmons Archana R. , Simmons Glennon W. , Ho Andy , Wong Jorge , Lu Karen H. , Bast Robert C. , McDevitt John T.
Published: April 2023

Supplementary Figure 1. Lower region of dose response curve to demonstrate limit of detection
Supplementary Figure 4 from 6-Shogaol from Dried Ginger Inhibits Growth of Prostate Cancer Cells Both In Vitro and In Vivo through Inhibition of STAT3 and NF-κB Signaling
Authors: Saha Achinto , Blando Jorge , Silver Eric , Beltran Linda , Sessler Jonathan , DiGiovanni John
Published: April 2023

PDF - 231K, Supplemental Figure 4. Effects of ginger components, 6-GIN and 6-PAR, on human and mouse PCa cells. DU145 and PC-3 cells were treated with 6-PAR, 6-GIN or 6-SHO followed by TNF-a and the levels of phospho IICBa, phospho NFICBp65 and NF-ICBp65 were measured by Western blot.
Supplementary Table 6 from Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening
Authors: Drescher Charles W. , Hawley Sarah , Thorpe Jason D. , Marticke Simone , McIntosh Martin , Gambhir Sanjiv S. , Urban Nicole
Published: April 2023

XLS file - 46K, Mortality reduction using estimates of serous cancer disease duration from physician survery (panel A)
Supplementary Figures 1-2, Table 3 from Mapping of Three Genetic Determinants of Susceptibility to Estrogen-Induced Mammary Cancer within the Emca8 Locus on Rat Chromosome 5
Authors: Schaffer Beverly S. , Leland-Wavrin Kristin M. , Kurz Scott G. , Colletti John A. , Seiler Nicole L. , Warren Christopher L. , Shull James D.
Published: April 2023

PDF file - 56K, Rat strain specific expression of Wnt4, Cd52 and Tspan1
Supplementary Tables 1 - 2 from An Evaluation of Novel, Lower-Cost Molecular Screening Tests for Human Papillomavirus in Rural China
Authors: Zhao Fang-Hui , Jeronimo Jose , Qiao You-Lin , Schweizer Johannes , Chen Wen , Valdez Melissa , Lu Peter , Zhang Xun , Kang Le-Ni , Bansil Pooja , Paul Proma , Mahoney Charles , Berard-Bergery Marthe , Bai Ping , Peck Roger , Li Jing , Chen Feng , Stoler Mark H. , Castle Philip E.
Published: April 2023

PDF file - 107K, Supplemental Tables 1A and 1B: Agreement between worst study histopathologic diagnosis. Supplemental Table 2: The relationship of E6 and DNA detection of human papillomavirus (HPV) genotypes 16, 18, and/or 45 (HPV16/18/45) on cervical exfoliated cells with HPV genotypes detected in the tissue of cervical intraepithelial neoplasia grade 2 (CIN2), grade 3 (CIN3), and cervical cancer, overall (all) and by clinical site.
Related Article from Screening for Oral Premalignancy and Cancer: What Platform and Which Biomarkers?
Authors: Lingen Mark W.
Published: April 2023

Related Article from Screening for Oral Premalignancy and Cancer: What Platform and Which Biomarkers?
Supplementary Table 3 from 17β-Estradiol and Tamoxifen Prevent Gastric Cancer by Modulating Leukocyte Recruitment and Oncogenic Pathways in Helicobacter Pylori–Infected INS-GAS Male Mice
Authors: Sheh Alexander , Ge Zhongming , Parry Nicola M.A. , Muthupalani Sureshkumar , Rager Julia E. , Raczynski Arkadiusz R. , Mobley Melissa W. , McCabe Amanda F. , Fry Rebecca C. , Wang Timothy C. , Fox James G.
Published: April 2023

PDF file - 52K, Networks associated to differentially expressed genes by Ingenuity Pathway Analysis. Genes in capital letters represent differentially expressed genes found within the network. A. Top networks associated with E2 treatment of infected male mice. B. Top networks associated with TAM treatment of infected male mice. C. Top 3 networks associated with commonly induced genes in both E2 and TAM treatments.
Supplementary Figure 2 from 17β-Estradiol and Tamoxifen Prevent Gastric Cancer by Modulating Leukocyte Recruitment and Oncogenic Pathways in Helicobacter Pylori–Infected INS-GAS Male Mice
Authors: Sheh Alexander , Ge Zhongming , Parry Nicola M.A. , Muthupalani Sureshkumar , Rager Julia E. , Raczynski Arkadiusz R. , Mobley Melissa W. , McCabe Amanda F. , Fry Rebecca C. , Wang Timothy C. , Fox James G.
Published: April 2023

PDF file - 419K, Significant molecular networks affected by Tamoxifen treatment (P=10-45). P-values represent the probability of these interactions occurring by chance.
Supplementary Figure 2 from Curcumin: A Double Hit on Malignant Mesothelioma
Authors: Miller Jill M. , Thompson Joyce K. , MacPherson Maximilian B. , Beuschel Stacie L. , Westbom Catherine M. , Sayan Mutlay , Shukla Arti
Published: April 2023

PDF file - 61K, Supplementary Figure 2. Curcumin treatment did not reduce MM tumor burden. (A) Allograft model comparing gavage administered curcumin to control group. (B) Allograft model comparing IP administered curcumin to control, cisplatin only and cisplatin plus curcumin groups. (C) Xenograft model comparing gavage and IP administered curcumin to control groups.
Supplementary Figure 1 from Curcumin: A Double Hit on Malignant Mesothelioma
Authors: Miller Jill M. , Thompson Joyce K. , MacPherson Maximilian B. , Beuschel Stacie L. , Westbom Catherine M. , Sayan Mutlay , Shukla Arti
Published: April 2023

PDF file - 62K, Supplementary Figure 1. Curcumin in combination with asbestos resulted in a synergistic effect on NLRP3 and pro-IL-1beta priming in human mesothelial cells. LP9 cells pretreated with curcumin (Cur 10 microM for 24-48 h) and exposed to asbestos (5 microg/cm2 for 24-48 h) showed increased NLRP3 (A) and pro-IL-1beta (B) mRNA levels with no significant change in caspase-1 activation (C) compared to control and asbestos exposed LP9 cells.
Supplementary Table 1 from miR-194 as a Predictor for Adenoma Recurrence in Patients with Advanced Colorectal Adenoma after Polypectomy
Authors: Wang Zhen-Hua , Ren Lin-Lin , Zheng Ping , Zheng Hai-Ming , Yu Ya-Nan , Wang Ji-Lin , Lin Yan-Wei , Chen Ying-Xuan , Ge Zhi-Zheng , Chen Xiao-Yu , Hong Jie , Fang Jing-Yuan
Published: April 2023

PDF - 111K, Characteristics of study population and advanced colorectal adenoma.
Supplementary Materials from miR-194 as a Predictor for Adenoma Recurrence in Patients with Advanced Colorectal Adenoma after Polypectomy
Authors: Wang Zhen-Hua , Ren Lin-Lin , Zheng Ping , Zheng Hai-Ming , Yu Ya-Nan , Wang Ji-Lin , Lin Yan-Wei , Chen Ying-Xuan , Ge Zhi-Zheng , Chen Xiao-Yu , Hong Jie , Fang Jing-Yuan
Published: April 2023

PDF - 69K, MiRNA microarray analysis.
Supplementary Table 5 from Aberrant DNA Methylation at Genes Associated with a Stem Cell-like Phenotype in Cholangiocarcinoma Tumors
Authors: Sriraksa Ruethairat , Zeller Constanze , Dai Wei , Siddiq Afshan , Walley Andrew J. , Limpaiboon Temduang , Brown Robert
Published: April 2023

PDF file - 334K, List of genes associated with hypermethylated CpG sites in 6 CCA compared to 6 matched adjacent normal samples.
Supplementary Table S3 from Autoantibody Signatures Combined with Epstein–Barr Virus Capsid Antigen-IgA as a Biomarker Panel for the Detection of Nasopharyngeal Carcinoma
Authors: Peng Yu-Hui , Xu Yi-Wei , Huang Li-Sheng , Zhai Tian-Tian , Dai Li-Hua , Qiu Si-Qi , Yang Yu-Su , Chen Wei-Zheng , Zhang Li-Qun , Li En-Min , Xu Li-Yan
Published: April 2023

Supplementary Table S3. Relationship between the expression levels of individual markers and clinical features in NPC patients in training set
Supplementary Figure from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis
Authors: Hikita Hayato , Kodama Takahiro , Tanaka Satoshi , Saito Yoshinobu , Nozaki Yasutoshi , Nakabori Tasuku , Shimizu Satoshi , Hayashi Yoshito , Li Wei , Shigekawa Minoru , Sakamori Ryotaro , Miyagi Takuya , Hiramatsu Naoki , Tatsumi Tomohide , Takehara Tetsuo
Published: April 2023

Supplementary Figure 3. Deep sequencing of almost all coding lesions of p53 and beta-catenin.
Supplementary Figure 2 from Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis
Authors: Hikita Hayato , Kodama Takahiro , Tanaka Satoshi , Saito Yoshinobu , Nozaki Yasutoshi , Nakabori Tasuku , Shimizu Satoshi , Hayashi Yoshito , Li Wei , Shigekawa Minoru , Sakamori Ryotaro , Miyagi Takuya , Hiramatsu Naoki , Tatsumi Tomohide , Takehara Tetsuo
Published: April 2023

Supplementary Figure 2. Bid deficiency suppresses hepatocyte apoptosis and oxidative stress in the livers of Mcl-1 KO mice.
Supplementary Figure S1 from Enhanced Antitumor Effects of Novel Intracellular Delivery of an Active Form of Menaquinone-4, Menahydroquinone-4, into Hepatocellular Carcinoma
Authors: Setoguchi Shuichi , Watase Daisuke , Matsunaga Kazuhisa , Matsubara Misa , Kubo Yohei , Kusuda Mariko , Nagata-Akaho Nami , Enjoji Munechika , Nakashima Manabu , Takeshita Morishige , Karube Yoshiharu , Takata Jiro
Published: April 2023

Supplementary Figure S1. Intracellular MKO and MK-4 levels after 24 h treatment with MKO in PLC/PRF/5 cells.
Supplementary Figure 1B from Prevention of Chemically Induced Urinary Bladder Cancers by Naproxen: Protocols to Reduce Gastric Toxicity in Humans Do Not Alter Preventive Efficacy
Authors: Lubet Ronald A. , Scheiman James M. , Bode Ann , White Jonathan , Minasian Lori , Juliana M. Margaret , Boring Daniel L. , Steele Vernon E. , Grubbs Clinton J.
Published: April 2023

Effects on Final tumor Weights of Naproxen and/or Omeprazole, Compared to Control
Supplemental Tables 1-3 from PAM50 and Risk of Recurrence Scores for Interval Breast Cancers
Authors: Puvanesarajah Samantha , Nyante Sarah J. , Kuzmiak Cherie M. , Chen Mengjie , Tse Chiu-Kit , Sun Xuezheng , Allott Emma H. , Kirk Erin L. , Carey Lisa A. , Perou Charles M. , Olshan Andrew F. , Henderson Louise M. , Troester Melissa A.
Published: April 2023

Supplemental Table 1 shows univariate odds ratios, Supplemental Table 2 shows adjusted odds ratios stratified by race, and SupplementalTable 3 compares associations using mode of detection derived using a 1 year vs. 2 year interval.
Supplementary Figures 1 and 2 from Relationship of Terminal Duct Lobular Unit Involution of the Breast with Area and Volume Mammographic Densities
Authors: Gierach Gretchen L. , Patel Deesha A. , Pfeiffer Ruth M. , Figueroa Jonine D. , Linville Laura , Papathomas Daphne , Johnson Jason M. , Chicoine Rachael E. , Herschorn Sally D. , Shepherd John A. , Wang Jeff , Malkov Serghei , Vacek Pamela M. , Weaver Donald L. , Fan Bo , Mahmoudzadeh Amir Pasha , Palakal Maya , Xiang Jackie , Oh Hannah , Horne Hisani N. , Sprague Brian L. , Hewitt Stephen M. , Brinton Louise A. , Sherman Mark E.
Published: April 2023

Supplementary Figure 1. Average Percent Dense Area by Age Supplementary Figure 2. Average Percent Dense Volume by Age.
Supplementary Legends from Preventive Anti-inflammatory Diet to Reduce Gastrointestinal Inflammation in Familial Adenomatous Polyposis Patients: A Prospective Pilot Study
Authors: Belfiore Antonino , Ciniselli Chiara Maura , Signoroni Stefano , Gariboldi Manuela , Mancini Andrea , Rivoltini Licia , Morelli Daniele , Masci Enzo , Bruno Eleonora , Macciotta Alessandra , Ricci Maria Teresa , Daveri Elena , Cattaneo Laura , Gargano Giuliana , Apolone Giovanni , Milione Massimo , Verderio Paolo , Pasanisi Patrizia , Vitellaro Marco
Published: April 2023

Supplementary Legends
Supplementary Data from Autofluorescence Imaging to Monitor the Progression of Oral Potentially Malignant Disorders
Authors: Cherry Katelin D. , Schwarz Richard A. , Yang Eric C. , Vohra Imran S. , Badaoui Hawraa , Williams Michelle D. , Vigneswaran Nadarajah , Gillenwater Ann M. , Richards-Kortum Rebecca
Published: April 2023

Explanation about how RG Ratio thresholds were found from previously published data.
Supplemental Table 1 from Epidemiologic Risk Factors in a Comparison of a Barrett Esophagus Registry (BarrettNET) and a Case–Control Population in Germany
Authors: Schmidt Melissa , Ankerst Donna P. , Chen Yiyao , Wiethaler Maria , Slotta-Huspenina Julia , Becker Karl-Friedrich , Horstmann Julia , Kohlmayer Florian , Lehmann Andreas , Linkohr Birgit , Strauch Konstantin , Schmid Roland M. , Quante Anne S. , Quante Michael
Published: April 2023

Supplemental Table 1: Comparison of epidemiological risk factors in Barrett patients (n= 587) and population controls (n= 587) matched by gender and age
Supplementary Data from Community-Based Upper Gastrointestinal Cancer Screening in a Randomized Controlled Trial: Baseline Results in a Non-high-incidence Area
Authors: Xiao Hai-Fan , Yan Shi-Peng , Chen Yan-fang , Shi Zhaohui , Zou Yan-Hua , Zhu Song-lin , Xu Ke-Kui , Song Ting , Liao Xian-Zhen
Published: April 2023

Table S1 Comparison of screening and control arm on potential risk factors for upper gastrointestinal cancerï¼›Table S2 Multivariate logistic analysis of participation rates for endoscopy
Figs S1-S8 from Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP)
Authors: Ulusan Ahmet M. , Rajendran Praveen , Dashwood Wan Mohaiza , Yavuz Omer F. , Kapoor Sabeeta , Gustafson Trace A. , Savage Michelle I. , Brown Powel H. , Sei Shizuko , Mohammed Altaf , Vilar Eduardo , Dashwood Roderick H.
Published: April 2023

Figs S1-S8, Supplementary Tables 1&2
Supplemental data from Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers
Authors: Yuan Jian-Min , Stepanov Irina , Murphy Sharon E. , Wang Renwei , Allen Sharon , Jensen Joni , Strayer Lori , Adams-Haduch Jennifer , Upadhyaya Pramod , Le Chap , Kurzer Mindy S. , Nelson Heather H. , Yu Mimi C. , Hatsukami Dorothy , Hecht Stephen S.
Published: April 2023

Table S1. Number of [pyridine-D4]NNK cigarettes smoked per day by study participants by treatment sequence groups and treatment period, The PEITC Intervention Study 2008-2013 Table S2. Spearman correlation coefficients between number of cigarettes per day and urinary metabolites of nicotine, NNK, [pyridine-D4]NNK, and PGEM and 8-iso-PGF2α at the end of smoking adaption period (visit 2), The PEITC Intervention Study 2008-2013 Table S3. Urinary Levels of Total ITC and PEITC-NAC by treatment sequence groups and treatment period, The PEITC Intervention Study 2008-2013 Table S4. Geometric means of urinary [pyridine-D4]NNK metabolites by study period and treatment sequence assignment, The PEITC Intervention Study 2008-2013 Table S5. Mean level of urinary levels of PEITC-NAC and total ITC during PEITC treatment by glutathione-S-transferase (GST) genotypes, The PEITC Intervention Study 2008-2013 Table S6. Urinary levels of NNK and nicotine metabolites by PEITC treatment, The PEITC Intervention Study 2008-2013 Figure S1. Overview of the metabolism of [pyridine-D4]NNK and [pyridine-D4]NNAL leading to DNA adducts and urinary metabolites. Figure S2. Overview of the study design for the PEITC trial.
Supplementary Table 1 from Obesity-Associated Alterations in Inflammation, Epigenetics, and Mammary Tumor Growth Persist in Formerly Obese Mice
Authors: Rossi Emily L. , de Angel Rebecca E. , Bowers Laura W. , Khatib Subreen A. , Smith Laura A. , Van Buren Eric , Bhardwaj Priya , Giri Dilip , Estecio Marcos R. , Troester Melissa A. , Hair Brionna Y. , Kirk Erin L. , Gong Ting , Shen Jianjun , Dannenberg Andrew J. , Hursting Stephen D.
Published: April 2023

IPA Biofunction Analysis. Significant disease or biofunction annotation implicated by IPA software.
S Table 3 from Physical Activity Plus Energy Restriction Prevents 4T1.2 Mammary Tumor Progression, MDSC Accumulation, and an Immunosuppressive Tumor Microenvironment
Authors: Turbitt William J. , Xu Yitong , Sosnoski Donna M. , Collins Shawntawnee D. , Meng Huicui , Mastro Andrea M. , Rogers Connie J.
Published: April 2023

Validation of gene array by qPCR of specific genes altered by PA and ER interventions
Supplemental Table S6 from Effect of Green Tea Supplements on Liver Enzyme Elevation: Results from a Randomized Intervention Study in the United States
Authors: Yu Zheming , Samavat Hamed , Dostal Allison M. , Wang Renwei , Torkelson Carolyn J. , Yang Chung S. , Butler Lesley M. , Kensler Thomas W. , Wu Anna H. , Kurzer Mindy S. , Yuan Jian-Min
Published: April 2023

Supplemental Table S6 displays the ALT level among 40 women whose ALT increased above 90 U/L over the course of treatment with GTE or placebo.
S Table 1 from Physical Activity Plus Energy Restriction Prevents 4T1.2 Mammary Tumor Progression, MDSC Accumulation, and an Immunosuppressive Tumor Microenvironment
Authors: Turbitt William J. , Xu Yitong , Sosnoski Donna M. , Collins Shawntawnee D. , Meng Huicui , Mastro Andrea M. , Rogers Connie J.
Published: April 2023

comparison of age, body weight and tumor measurements among young and middle aged mice
Supplementary Text from Three-Year Interval for the Multi-Target Stool DNA Test for Colorectal Cancer Screening: A Longitudinal Study
Authors: Imperiale Thomas F. , Lavin Philip T. , Marti Tara N. , Jakubowski Debbie , Itzkowitz Steven H. , May Folasade P. , Limburg Paul J. , Sweetser Seth , Daghestani Anas , Berger Barry M.
Published: April 2023

This Supplemental Text file provides additional information regarding the clinical procedures and sample processing/lab procedures, as well as an explanation of the sensitivity and robustness analyses.
Supplementary Figure 8 from Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Authors: Aarts Marieke , Sharpe Rachel , Garcia-Murillas Isaac , Gevensleben Heidrun , Hurd Melissa S. , Shumway Stuart D. , Toniatti Carlo , Ashworth Alan , Turner Nicholas C.
Published: April 2023

PDF file - 54K, Molecular determinants of unscheduled mitotic entry
Supplementary Figure S4 from Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Authors: Bardelli Alberto , Corso Simona , Bertotti Andrea , Hobor Sebastijan , Valtorta Emanuele , Siravegna Giulia , Sartore-Bianchi Andrea , Scala Elisa , Cassingena Andrea , Zecchin Davide , Apicella Maria , Migliardi Giorgia , Galimi Francesco , Lauricella Calogero , Zanon Carlo , Perera Timothy , Veronese Silvio , Corti Giorgio , Amatu Alessio , Gambacorta Marcello , Diaz Luis A. , Sausen Mark , Velculescu Victor E. , Comoglio Paolo , Trusolino Livio , Di Nicolantonio Federica , Giordano Silvia , Siena Salvatore
Published: April 2023

Supplementary Figure S4 - PDF file 19K, Ectopic expression of MET in cetuximab sensitive DIFI and LIM1215 cell lines
Supplementary Figure 4 from The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer
Authors: McKie Arthur B. , Vaughan Sebastian , Zanini Elisa , Okon Imoh S. , Louis Louay , de Sousa Camila , Greene Mark I. , Wang Qiang , Agarwal Roshan , Shaposhnikov Dmitry , Wong Joshua L. C. , Gungor Hatice , Janczar Szymon , El-Bahrawy Mona , Lam Eric W-F. , Chayen Naomi E. , Gabra Hani
Published: April 2023

PDF file - 73K
Supplementary Figure 2 from The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer
Authors: McKie Arthur B. , Vaughan Sebastian , Zanini Elisa , Okon Imoh S. , Louis Louay , de Sousa Camila , Greene Mark I. , Wang Qiang , Agarwal Roshan , Shaposhnikov Dmitry , Wong Joshua L. C. , Gungor Hatice , Janczar Szymon , El-Bahrawy Mona , Lam Eric W-F. , Chayen Naomi E. , Gabra Hani
Published: April 2023

PDF file - 93K
Supplementary Figure S5 from Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Authors: Montero-Conde Cristina , Ruiz-Llorente Sergio , Dominguez Jose M. , Knauf Jeffrey A. , Viale Agnes , Sherman Eric J. , Ryder Mabel , Ghossein Ronald A. , Rosen Neal , Fagin James A.
Published: April 2023

Supplementary Figure S5 PDF file - 32K, PLX4032 decreases occupancy of the HER3 gene promoter in SW1736 thyroid cancer cells. A, CtBP1 or CtBP2 chromatin immunoprecipitation assays were performed in SW1736 cells treated with or without 2 ��M PLX4032 for 24 or 48 h as described in Figure 5F. Graph shows normalized Q-RT-PCR HER3 data of the immunoprecipitated complexes compared to input lysate. Data represent mean +/- SD of two independent biological replicates performed in quintuplicate. ***p<0.001
Supplementary Figure S4 from Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Authors: Montero-Conde Cristina , Ruiz-Llorente Sergio , Dominguez Jose M. , Knauf Jeffrey A. , Viale Agnes , Sherman Eric J. , Ryder Mabel , Ghossein Ronald A. , Rosen Neal , Fagin James A.
Published: April 2023

Supplementary Figure S4 PDF file - 81K, Exogenous ligand-dependence of PLX4032-induced HER3 activation in melanoma cell lines. A, lysates of melanoma cell lines treated with 2 �gM PLX4032 for the indicated times were immunoblotted for tHER3. B, response of SK-MEL-28 cells to ligand induced activation of HER2/HER3 after exposure to PLX4032. Cells were treated with PLX4032 for 48 h, and then with or without 50 ng/ml of NRG1 for 5 minutes. RAS-GTP was detected by IP with RAS binding domain of CRAF (RBD) followed by Western blotting with anti-RAS. Input lysates were immunoblotted with the indicated antibodies. C, SK-MEL-28 cells were treated with increasing concentrations of PLX4032 alone (dark grey) or in combination with NRG1 (red). Cells were collected and counted after 4 days of treatment. Bars represent percent change (mean +/- SD) in cell counts of triplicate wells compared to untreated cells. *p < 0.05
Supplementary Table 3 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN
Authors: Bjerke Lynn , Mackay Alan , Nandhabalan Meera , Burford Anna , Jury Alexa , Popov Sergey , Bax Dorine A. , Carvalho Diana , Taylor Kathryn R. , Vinci Maria , Bajrami Ilirjana , McGonnell Imelda M. , Lord Christopher J. , Reis Rui M. , Hargrave Darren , Ashworth Alan , Workman Paul , Jones Chris
Published: April 2023

XLSX file - 33K, Core enrichment of genes between differential expression analysis in primary tumours and ChIP-Seq in paediatric GBM cells.
Supplementary Figure 5 from Antagonism of Inhibitor of Apoptosis Proteins Increases Bone Metastasis via Unexpected Osteoclast Activation
Authors: Yang Chang , Davis Jennifer L. , Zeng Rong , Vora Paras , Su Xinming , Collins Lynne I. , Vangveravong Suwanna , Mach Robert H. , Piwnica-Worms David , Weilbaecher Katherine N. , Faccio Roberta , Veis Novack Deborah
Published: April 2023

PDF file - 1835K, RT-PCR showing BV6 activation of p65, and lack of effect of p65 depletion on BV6 osteoclastogenic effects
Supplementary Figure 3 from Antagonism of Inhibitor of Apoptosis Proteins Increases Bone Metastasis via Unexpected Osteoclast Activation
Authors: Yang Chang , Davis Jennifer L. , Zeng Rong , Vora Paras , Su Xinming , Collins Lynne I. , Vangveravong Suwanna , Mach Robert H. , Piwnica-Worms David , Weilbaecher Katherine N. , Faccio Roberta , Veis Novack Deborah
Published: April 2023

PDF file - 3716K,Osteoclastogenic response to constant BV6 and ML183, and effect of BV6 on osteoblastogenesis in culture
Figure S8 from Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity
Authors: Mathew Lijoy K. , Lee Samuel S. , Skuli Nicolas , Rao Shilpa , Keith Brian , Nathanson Katherine L. , Lal Priti , Simon M. Celeste
Published: April 2023

PDF file 27K, GATA3 expression in ccRCCs
Supplementary Figure S1 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Authors: Ingle James N. , Liu Mohan , Wickerham D. Lawrence , Schaid Daniel J. , Wang Liewei , Mushiroda Taisei , Kubo Michiaki , Costantino Joseph P. , Vogel Victor G. , Paik Soonmyung , Goetz Matthew P. , Ames Matthew M. , Jenkins Gregory D. , Batzler Anthony , Carlson Erin E. , Flockhart David A. , Wolmark Norman , Nakamura Yusuke , Weinshilboum Richard M.
Published: April 2023

Supplementary Figure S1 - PDF file 43K, Q-Q plot
Supplementary Figure 2 from Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes
Authors: Pedersen Malin , Küsters-Vandevelde Heidi V.N. , Viros Amaya , Groenen Patricia J.T.A. , Sanchez-Laorden Berta , Gilhuis Jacobus H. , van Engen-van Grunsven Ilse A. , Renier Willy , Schieving Jolanda , Niculescu-Duvaz Ion , Springer Caroline J. , Küsters Benno , Wesseling Pieter , Blokx Willeke A.M. , Marais Richard
Published: April 2023

Supplementary Figure 2 PDF file - 394K,Data are presented to show that congenital expression of NRASG12D in mouse melanocytes does not affect eyes or heart development
Supplementary Methods from Haploinsufficiency of an RB–E2F1–Condensin II Complex Leads to Aberrant Replication and Aneuploidy
Authors: Coschi Courtney H. , Ishak Charles A. , Gallo David , Marshall Aren , Talluri Srikanth , Wang Jianxin , Cecchini Matthew J. , Martens Alison L. , Percy Vanessa , Welch Ian , Boutros Paul C. , Brown Grant W. , Dick Frederick A.
Published: April 2023

PDF file 125K, Detailed methods for ChIP, microscopy, and computational analysis. Lists of cell lines and antibodies used are included
Supplementary Figure Legends from Haploinsufficiency of an RB–E2F1–Condensin II Complex Leads to Aberrant Replication and Aneuploidy
Authors: Coschi Courtney H. , Ishak Charles A. , Gallo David , Marshall Aren , Talluri Srikanth , Wang Jianxin , Cecchini Matthew J. , Martens Alison L. , Percy Vanessa , Welch Ian , Boutros Paul C. , Brown Grant W. , Dick Frederick A.
Published: April 2023

PDF fie 148K, Description of additional genotypes of cells analyzed for gammaH2AX distribution and detailed instability phenotypes of heterozygous cells
Supplementary Methods and Legends from Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
Authors: Malchers Florian , Dietlein Felix , Schöttle Jakob , Lu Xin , Nogova Lucia , Albus Kerstin , Fernandez-Cuesta Lynnette , Heuckmann Johannes M. , Gautschi Oliver , Diebold Joachim , Plenker Dennis , Gardizi Masyar , Scheffler Matthias , Bos Marc , Seidel Danila , Leenders Frauke , Richters André , Peifer Martin , Florin Alexandra , Mainkar Prathama S. , Karre Nagaraju , Chandrasekhar Srivari , George Julie , Silling Steffi , Rauh Daniel , Zander Thomas , Ullrich Roland T. , Reinhardt H. Christian , Ringeisen Francois , Büttner Reinhard , Heukamp Lukas C. , Wolf Jürgen , Thomas Roman K.
Published: April 2023

PDF file 136K,Methods: Additional information on experimental techniques and data analysis. Legends: describing supplementary figures S1-S14
Supplementary Figure 1 from RNA Helicase A Is a Downstream Mediator of KIF1Bβ Tumor-Suppressor Function in Neuroblastoma
Authors: Chen Zhi Xiong , Wallis Karin , Fell Stuart M. , Sobrado Veronica R. , Hemmer Marie C. , Ramsköld Daniel , Hellman Ulf , Sandberg Rickard , Kenchappa Rajappa S. , Martinson Tommy , Johnsen John I. , Kogner Per , Schlisio Susanne
Published: April 2023

PDF file 723K, Figure S1, related to Figure 1. DHX9 is a binding partner of KIF1Bβ apoptotic domain
Supplementary methods, figures and legends from Defective Stromal Remodeling and Neutrophil Extracellular Traps in Lymphoid Tissues Favor the Transition from Autoimmunity to Lymphoma
Authors: Sangaletti Sabina , Tripodo Claudio , Vitali Caterina , Portararo Paola , Guarnotta Carla , Casalini Patrizia , Cappetti Barbara , Miotti Silvia , Pinciroli Patrizia , Fuligni Fabio , Fais Franco , Piccaluga Pier Paolo , Colombo Mario P.
Published: April 2023

PDF file 1045K, Merged file (pdf) including methods, figures and legends
Figure S3 from A High-Throughput Fluorimetric Assay for 2-Hydroxyglutarate Identifies Zaprinast as a Glutaminase Inhibitor
Authors: Elhammali Adnan , Ippolito Joseph E. , Collins Lynne , Crowley Jan , Marasa Jayne , Piwnica-Worms David
Published: April 2023

PDF file 20K, cGMP does not inhibit GLS1 activity PDF. Enzyme activity of purified, full length, human glutaminase treated with increasing amounts of cGMP in the presence of 10 mM glutamine
Supplementary Figure 2 from Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype
Authors: Sawyer Sarah L. , Tian Lei , Kähkönen Marketta , Schwartzentruber Jeremy , Kircher Martin , Majewski Jacek , Dyment David A. , Innes A. Micheil , Boycott Kym M. , Moreau Lisa A. , Moilanen Jukka S. , Greenberg Roger A.
Published: April 2023

Supplementary Figure 2. Functional analysis of the BRCA1 (p.Arg1699Trp) mutation.
Supplementary Figure Legends from Mutant N-RAS Protects Colorectal Cancer Cells from Stress-Induced Apoptosis and Contributes to Cancer Development and Progression
Authors: Wang Yufang , Velho Sérgia , Vakiani Efsevia , Peng Shouyong , Bass Adam J. , Chu Gerald C. , Gierut Jessica , Bugni James M. , Der Channing J. , Philips Mark , Solit David B. , Haigis Kevin M.
Published: April 2023

Supplementary Figure Legends PDF file 72K, Legends for Supplementary Figures 1-6
Supplementary Figures S1 - S10, Tables S1 - S3 from NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition
Authors: Garcia-Rendueles Maria E.R. , Ricarte-Filho Julio C. , Untch Brian R. , Landa Iňigo , Knauf Jeffrey A. , Voza Francesca , Smith Vicki E. , Ganly Ian , Taylor Barry S. , Persaud Yogindra , Oler Gisele , Fang Yuqiang , Jhanwar Suresh C. , Viale Agnes , Heguy Adriana , Huberman Kety H. , Giancotti Filippo , Ghossein Ronald , Fagin James A.
Published: April 2023

Supplementary Figure S1. Loss of heterozygosity of Ch22q genes in poorly differentiated (PDTC) and anaplastic thyroid cancers (ATC). Supplementary Figure S2. Focal NF2-exon 4 homozygous deletion in KHM-5M anaplastic thyroid cancer cells. Supplementary Figure S3. FISH for NF2 in anaplastic thyroid cancers. Supplementary Figure S4. NF2/Merlin defects in thyroid cancer cell lines. Supplementary Figure S5. Merlin inhibits RAC1-PAK activity. Supplementary Figure S6. Merlin effects on EGFR signaling and growth of RAS mutant thyroid cancer cell lines. Supplementary Figure S7. PCR of genomic DNA from mouse thyroid tissues of the indicated genotypes with primers that distinguish wild-type from mutant Hras alleles. Supplementary Figure S8. TEAD1 is the most abundant TEAD isoform in thyroid cancer cells. Supplementary Figure S9. A) Left, Concentration-dependent growth inhibitory effects of the MEK inhibitor selumetinib (AZD6244) in RAS mutant thyroid cancer cell lines cells. Black, null/low NF2. Red, wt NF2. The IC50 of each cell line is shown in the boxed legend. Right, Western blots for merlin, pMEK and pERK in the cell lines studied. B) C643 cells expressing scrambled (pLKO.1) or shNF2 were treated with FRAX, AZD or their combination at the indicated concentrations (nM) in 1 percent of serum. Cells were counted at 6 days (*p<5 x E -3). Supplementary Figure S10. A) Tumor doubling time of the indicated mouse models of PDTC.B) Kaplan-Meier survival curves of TPO-Cre, TPO-Cre/FR-HrasG12V/NF2flox2, TPO-Cre/FR-HrasG12V/PTENflox2 and TPO-Cre/FRHrasG12V/p53flox2 mice. Left, HrasG12V heterozygotes. Right, HrasG12V homozygotes. (*p < 3 x E-2, **p < 1 x E -4). Supplementary Table S1. 22q loss is associated with RAS mutations in PTC, PDTC and ATC. Supplementary Table S2. Penetrance of thyroid cancer in HRASG12V/NF2-null mice. Supplementary Table S3. PCR primer sequences.
Supplementary Methods, Figure Legends from Lysine Demethylase KDM4A Associates with Translation Machinery and Regulates Protein Synthesis
Authors: Van Rechem Capucine , Black Joshua C. , Boukhali Myriam , Aryee Martin J. , Gräslund Susanne , Haas Wilhelm , Benes Cyril H. , Whetstine Johnathan R.
Published: April 2023

This file contains legends and information about supplemental material.
Supplementary Methods, Figure Legend, Tables 1 - 6 from A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
Authors: Joseph James D. , Lu Nhin , Qian Jing , Sensintaffar John , Shao Gang , Brigham Dan , Moon Michael , Maneval Edna Chow , Chen Isan , Darimont Beatrice , Hager Jeffrey H.
Published: April 2023

PDF file - 183K, Supplementary Table S1. 1st and 2nd generation AR antagonist activity on F876L-AR. Supplementary Table S2. LNCaP/SRF876L Xenograft Pharmacokinetics Supplementary Table S3. AR nucleotide changes monitored by BEAMing assay Supplementary Table S4. Primary F876L BEAMing of ARN-509-001 Patients Supplementary Table S5. Transcriptional Real-time PCR Oligonucleotide Sequence Supplementary Table S6. ChIP Real-time PCR Oligonucleotide Sequence
Supplementary Figures 1 - 11 from A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
Authors: Joseph James D. , Lu Nhin , Qian Jing , Sensintaffar John , Shao Gang , Brigham Dan , Moon Michael , Maneval Edna Chow , Chen Isan , Darimont Beatrice , Hager Jeffrey H.
Published: April 2023

PDF file - 401K, Supplementary Figure S1. Parental and 2nd generation anti-androgen resistant cell line proliferation. Supplementary Figure S2. AR levels in parental and 2nd generation anti-androgen resistant cell lines. Supplementary Figure S3. AR levels in transfection assays. Supplementary Figure S4. Transcriptional reporter assay of AR mutants. Supplementary Figure S5. Ligand binding domain of the AR bound to DHT (1T7T;(1)). Supplementary Figure S6. Competitive binding assay of wild-type AR vs. F876L AR. Supplementary Figure S7. AR levels in AR overexpressing cell lines. Supplementary Figure S8. LNCaP/AR(cs), LNCaP/SRF876L and LNCaP/pCDNAF876L cell proliferation. Supplementary Figure S9. Transcriptional activity of ARN-509 and enzalutamide in LNCaP/pCDNAF876L cells. Supplementary Figure S10. AR ChIP analysis of AR target genes. Supplementary Figure S11. PSA response for 3 patients with detectable AR F876L mutation.
Supplementary Figures from mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
Authors: Faber Anthony C. , Coffee Erin M. , Costa Carlotta , Dastur Anahita , Ebi Hiromichi , Hata Aaron N. , Yeo Alan T. , Edelman Elena J. , Song Youngchul , Tam Ah Ting , Boisvert Jessica L. , Milano Randy J. , Roper Jatin , Kodack David P. , Jain Rakesh K. , Corcoran Ryan B. , Rivera Miguel N. , Ramaswamy Sridhar , Hung Kenneth E. , Benes Cyril H. , Engelman Jeffrey A.
Published: April 2023

PDF file 764K, Supp. Figures 1-10 include data describing in vitro and in vivo experiments in support of Faber at al
Supplementary Figure 1 from p38MAPK Plays a Crucial Role in Stromal-Mediated Tumorigenesis
Authors: Alspach Elise , Flanagan Kevin C. , Luo Xianmin , Ruhland Megan K. , Huang Hui , Pazolli Ermira , Donlin Maureen J. , Marsh Timothy , Piwnica-Worms David , Monahan Joseph , Novack Deborah V. , McAllister Sandra S. , Stewart Sheila A.
Published: April 2023

PDF file 194K, Senescence-associated beta-galactosidase staining of BJ fibroblasts and treatment of HaCaT-CBR cells with the p38MAPK small-molecule inhibitor SB203580
Supplementary Figure 4 from Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
Authors: Levy Jean M. Mulcahy , Thompson Joshua C. , Griesinger Andrea M. , Amani Vladimir , Donson Andrew M. , Birks Diane K. , Morgan Michael J. , Mirsky David M. , Handler Michael H. , Foreman Nicholas K. , Thorburn Andrew
Published: April 2023

PDF file 17K, Growth curve with vemurafenib treatments
Supplementary Tables from Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
Authors: Horwitz Elad , Stein Ilan , Andreozzi Mariacarla , Nemeth Julia , Shoham Avivit , Pappo Orit , Schweitzer Nora , Tornillo Luigi , Kanarek Naama , Quagliata Luca , Zreik Farid , Porat Rinnat M. , Finkelstein Rutie , Reuter Hendrik , Koschny Ronald , Ganten Tom , Mogler Carolin , Shibolet Oren , Hess Jochen , Breuhahn Kai , Grunewald Myriam , Schirmacher Peter , Vogel Arndt , Terracciano Luigi , Angel Peter , Ben-Neriah Yinon , Pikarsky Eli
Published: April 2023

PDF file 145K, Tables containing information about genes residing on the amplicon and compiled data
Supplementary Figures from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Authors: Morris Erick J. , Jha Sharda , Restaino Clifford R. , Dayananth Priya , Zhu Hugh , Cooper Alan , Carr Donna , Deng Yongi , Jin Weihong , Black Stuart , Long Brian , Liu Jenny , DiNunzio Edward , Windsor William , Zhang Rumin , Zhao Shuxia , Angagaw Minilik H. , Pinheiro Elaine M. , Desai Jagdish , Xiao Li , Shipps Gerald , Hruza Alan , Wang James , Kelly Joe , Paliwal Sunil , Gao Xiaolei , Babu Boga Sobhana , Zhu Liang , Daublain Pierre , Zhang Ling , Lutterbach Bart A. , Pelletier Marc R. , Philippar Ulrike , Siliphaivanh Phieng , Witter David , Kirschmeier Paul , Bishop W. Robert , Hicklin Daniel , Gilliland D. Gary , Jayaraman Lata , Zawel Leigh , Fawell Stephen , Samatar Ahmed A.
Published: April 2023

Supplementary Figures - PDF file 1385K, File contains Supplementary figures of resistant cell lines, proliferation assay of a panel of cell lines, TdF binding assay transcriptional out and kinome selectivity
Supplementary Figure 3 from A Small-Molecule c-Rel Inhibitor Reduces Alloactivation of T Cells without Compromising Antitumor Activity
Authors: Shono Yusuke , Tuckett Andrea Z. , Ouk Samedy , Liou Hsiou-Chi , Altan-Bonnet Grégoire , Tsai Jennifer J. , Oyler Jennifer E. , Smith Odette M. , West Mallory L. , Singer Natalie V. , Doubrovina Ekaterina , Pankov Dmitry , Undhad Chandresh V. , Murphy George F. , Lezcano Cecilia , Liu Chen , O'Reilly Richard J. , van den Brink Marcel R.M. , Zakrzewski Johannes L.
Published: April 2023

PDF file 128KB, Treg depletion from c-Rel deficient donor T-cells results in exacerbated GVHD
Supplementary Methods, Figure Legends from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
Authors: Blake Stephen J. , Stannard Kimberley , Liu Jing , Allen Stacey , Yong Michelle C.R. , Mittal Deepak , Aguilera Amelia Roman , Miles John J. , Lutzky Viviana P. , de Andrade Lucas Ferrari , Martinet Ludovic , Colonna Marco , Takeda Kazuyoshi , Kühnel Florian , Gurlevik Engin , Bernhardt Günter , Teng Michele W.L. , Smyth Mark J.
Published: April 2023

Supplementary Methods, Figure Legends
Supplementary Figure S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Authors: Peng Weiyi , Chen Jie Qing , Liu Chengwen , Malu Shruti , Creasy Caitlin , Tetzlaff Michael T. , Xu Chunyu , McKenzie Jodi A. , Zhang Chunlei , Liang Xiaoxuan , Williams Leila J. , Deng Wanleng , Chen Guo , Mbofung Rina , Lazar Alexander J. , Torres-Cabala Carlos A. , Cooper Zachary A. , Chen Pei-Ling , Tieu Trang N. , Spranger Stefani , Yu Xiaoxing , Bernatchez Chantale , Forget Marie-Andree , Haymaker Cara , Amaria Rodabe , McQuade Jennifer L. , Glitza Isabella C. , Cascone Tina , Li Haiyan S. , Kwong Lawrence N. , Heffernan Timothy P. , Hu Jianhua , Bassett Roland L. , Bosenberg Marcus W. , Woodman Scott E. , Overwijk Willem W. , Lizée Gregory , Roszik Jason , Gajewski Thomas F. , Wargo Jennifer A. , Gershenwald Jeffrey E. , Radvanyi Laszlo , Davies Michael A. , Hwu Patrick
Published: April 2023

Examples of increased VEGF expression in regions with loss of PTEN in melanoma patients with heterogeneous PTEN expression.
Supplementary Methods from ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Authors: Shen Jianfeng , Peng Yang , Wei Leizhen , Zhang Wei , Yang Lin , Lan Li , Kapoor Prabodh , Ju Zhenlin , Mo Qianxing , Shih Ie-Ming , Uray Ivan P. , Wu Xiangwei , Brown Powel H. , Shen Xuetong , Mills Gordon B. , Peng Guang
Published: April 2023

Supplementary Methods from ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Supplementary Figure Legends from In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K–AKT Signaling at Endosomes
Authors: Li Chew Chen , Lunardi Andrea , Gulluni Federico , Ruan Daniel T. , Chen Ming , Salmena Leonardo , Nishino Michiya , Papa Antonella , Ng Christopher , Fung Jacqueline , Clohessy John G. , Sasaki Junko , Sasaki Takehiko , Bronson Roderick T. , Hirsch Emilio , Pandolfi Pier Paolo
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 7 from In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K–AKT Signaling at Endosomes
Authors: Li Chew Chen , Lunardi Andrea , Gulluni Federico , Ruan Daniel T. , Chen Ming , Salmena Leonardo , Nishino Michiya , Papa Antonella , Ng Christopher , Fung Jacqueline , Clohessy John G. , Sasaki Junko , Sasaki Takehiko , Bronson Roderick T. , Hirsch Emilio , Pandolfi Pier Paolo
Published: April 2023

Supplementary Figure 7. INPP4B loss does not produce any morphological or cytoskeletal differences.
Supplementary Figure 4 from Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Authors: Kaneda Megan M. , Cappello Paola , Nguyen Abraham V. , Ralainirina Natacha , Hardamon Chanae R. , Foubert Philippe , Schmid Michael C. , Sun Ping , Mose Evangeline , Bouvet Michael , Lowy Andrew M. , Valasek Mark A. , Sasik Roman , Novelli Francesco , Hirsch Emilio , Varner Judith A.
Published: April 2023

Effect of PI3Kγ inhibitors on PDAC growth and survival.
Supplementary Figure 4 from In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K–AKT Signaling at Endosomes
Authors: Li Chew Chen , Lunardi Andrea , Gulluni Federico , Ruan Daniel T. , Chen Ming , Salmena Leonardo , Nishino Michiya , Papa Antonella , Ng Christopher , Fung Jacqueline , Clohessy John G. , Sasaki Junko , Sasaki Takehiko , Bronson Roderick T. , Hirsch Emilio , Pandolfi Pier Paolo
Published: April 2023

Supplementary Figure 4. Loss of Inpp4b in MEFs lead to increased Akt activation.
Supplementary Figure Legends from INPP4B Is a PtdIns(3,4,5)P3 Phosphatase That Can Act as a Tumor Suppressor
Authors: Kofuji Satoshi , Kimura Hirotaka , Nakanishi Hiroki , Nanjo Hiroshi , Takasuga Shunsuke , Liu Hui , Eguchi Satoshi , Nakamura Ryotaro , Itoh Reietsu , Ueno Noriko , Asanuma Ken , Huang Mingguo , Koizumi Atsushi , Habuchi Tomonori , Yamazaki Masakazu , Suzuki Akira , Sasaki Junko , Sasaki Takehiko
Published: April 2023

Supplementary Figure Legends
Supplementary Table S6 from DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia
Authors: Meyer Sara E. , Qin Tingting , Muench David E. , Masuda Kohei , Venkatasubramanian Meenakshi , Orr Emily , Suarez Lauren , Gore Steven D. , Delwel Ruud , Paietta Elisabeth , Tallman Martin S. , Fernandez Hugo , Melnick Ari , Le Beau Michelle M. , Kogan Scott , Salomonis Nathan , Figueroa Maria E. , Grimes H. Leighton
Published: April 2023

DMR in DNMT3A rescued c-Kit+ Flt3ITD/ITD;Dnmt3afl/fl MxCre cells versus c-Kit+ Flt3ITD/ITD;Dnmt3afl/fl MxCre empty vector control cells.
Supplementary Table S5 from DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia
Authors: Meyer Sara E. , Qin Tingting , Muench David E. , Masuda Kohei , Venkatasubramanian Meenakshi , Orr Emily , Suarez Lauren , Gore Steven D. , Delwel Ruud , Paietta Elisabeth , Tallman Martin S. , Fernandez Hugo , Melnick Ari , Le Beau Michelle M. , Kogan Scott , Salomonis Nathan , Figueroa Maria E. , Grimes H. Leighton
Published: April 2023

ICGS HOPACH gene expression clustering results performed on RNA-Seq data from 96 single Flt3ITD/ITD;Dnmt3afl/fl MxCre AML cells.
Supplementary Methods from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Authors: de Bono Johann , Ramanathan Ramesh K. , Mina Lida , Chugh Rashmi , Glaspy John , Rafii Saeed , Kaye Stan , Sachdev Jasgit , Heymach John , Smith David C. , Henshaw Joshua W. , Herriott Ashleigh , Patterson Miranda , Curtin Nicola J. , Byers Lauren Averett , Wainberg Zev A.
Published: April 2023

Supplementary Methods includes additional details on these topics: tumors eligible for dose escalation phase; tumors eligible for dose expansion phase; patients enrolled using a local laboratory; study design and participants; additional inclusion criteria; full list of exclusion criteria; study treatment; study procedures; pharmacodynamic (PD) analysis; inhibition of PBMC PARP activity.
Supplementary Figure S1 from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Authors: de Bono Johann , Ramanathan Ramesh K. , Mina Lida , Chugh Rashmi , Glaspy John , Rafii Saeed , Kaye Stan , Sachdev Jasgit , Heymach John , Smith David C. , Henshaw Joshua W. , Herriott Ashleigh , Patterson Miranda , Curtin Nicola J. , Byers Lauren Averett , Wainberg Zev A.
Published: April 2023

Supplementary Figure S1. Talazoparib inhibition of PBMC PARP activity.
Supplementary Figures 1 - 6, Tables 1 - 2 from A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer
Authors: Vijai Joseph , Topka Sabine , Villano Danylo , Ravichandran Vignesh , Maxwell Kara N. , Maria Ann , Thomas Tinu , Gaddam Pragna , Lincoln Anne , Kazzaz Sarah , Wenz Brandon , Carmi Shai , Schrader Kasmintan A. , Hart Steven N. , Lipkin Steve M. , Neuhausen Susan L. , Walsh Michael F. , Zhang Liying , Lejbkowicz Flavio , Rennert Hedy , Stadler Zsofia K. , Robson Mark , Weitzel Jeffrey N. , Daly Mark J. , Couch Fergus J. , Nathanson Katherine L. , Norton Larry , Rennert Gad , Offit Kenneth
Published: April 2023

Supplementary Figure 1. Electropherogram. Supplementary Figure 2. Ramachandran plot. Supplementary Figure 3. Modeling ERCC3 R109X via CRISPR/Cas9 genome editing. Supplementary Figure 4. Haplotype analyses from the TAGC heterozygote carriers. Supplementary Figure 5. ERCC3 mutations present in the cBioPortal (MSKCC) datasets. Supplementary Figure 6. ERCC3 transcript levels in patient derived whole blood. Supplementary Table 1. Family history and pathology information on R109X carriers. Supplementary Table 2. Identity of mutations in HMLE cell lines generated by CRISPR/Cas9.